We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ACT Funds Brown Cancer Center Research Scientist to Accelerate Identification of Clinical Candidates
News

ACT Funds Brown Cancer Center Research Scientist to Accelerate Identification of Clinical Candidates

ACT Funds Brown Cancer Center Research Scientist to Accelerate Identification of Clinical Candidates
News

ACT Funds Brown Cancer Center Research Scientist to Accelerate Identification of Clinical Candidates

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ACT Funds Brown Cancer Center Research Scientist to Accelerate Identification of Clinical Candidates"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Advanced Cancer Therapeutics (ACT) has announced that it has signed an agreement to leverage the computational chemistry expertise of Dr. John Trent, Associate Professor, Department of Medicine at the University of Louisville’s James Graham Brown Cancer Center (Brown Cancer Center), to accelerate the identification of new clinical candidates for the prevention and treatment of cancer.

“His computational chemistry efforts will complement our current medicinal chemistry efforts which look at the crystal structure of each target to help ACT rationally design and identify the best anti-cancer products.”

As part of this agreement, over the next twelve months Dr. Trent will provide contract work for ACT and interface with ACT’s medicinal chemists to identify the best preclinical candidates for ACT’s top two small molecule compound programs addressing two novel cancer targets in the area of cancer metabolism. These programs include 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) and Choline Kinase (CK).

ACT obtained worldwide exclusive licenses from the Brown Cancer Center to the PFKFB program in 2008 and for the CK program in 2009.

To date, ACT has rationally designed and synthesized over 200 novel small molecule compounds against both PFKFB and CK targets. The company has been able to identify several potential preclinical candidates with desired selectivity and potency parameters and other attractive attributes, bringing them closer to initiating toxicology studies that would support an investigational new drug (IND) application.

Establishing this collaboration with Dr. Trent will allow the company to integrate computational chemistry into ACT’s medicinal chemistry activities and should enable ACT to select the best preclinical candidate for both the PFKFB and CK program, as well as prioritize related backup compounds.

“ACT is pleased to be working with Dr. Trent as we collaborate to accelerate the discovery process to develop potentially lifesaving therapeutics for cancer patients,” said Randall Riggs, President & CEO of ACT. “His computational chemistry efforts will complement our current medicinal chemistry efforts which look at the crystal structure of each target to help ACT rationally design and rapidly identify the best anti-cancer products.”
Advertisement